Safety and tolerability of a novel tissue factor/factor VIIa inhibitor rNAPc2 in patients with non-ST elevation acute coronary syndrome managed invasively: Results from the ANTHEM-TIMI 32 Trial

Authors

Marc Schweiger MD, Baystate HealthFollow

Author Department

Medicine

Document Type

Presentations, Research

Publication Date

3-1-2007

Recommended Citation

American College of Cardiology 56th Annual Scientific Session. J Am Coll Cardiol 2007;49:196A.